双歧四联活菌多药联合对根除幽门螺杆菌患者的临床疗效观察

目的:研究双歧四联活菌多药联合对根除幽门螺杆菌(Helicobacter pylori,Hp)患者的临床疗效。方法:从2012年3月到2013年3月,共计60例病患因腹部不适就诊。以数字法随机分成实验组及对照组。对照组以埃索美拉唑镁肠溶片(剂量为20 mg bid)和胶体酒石酸铋钠(剂量为165 mg qid)以及克拉霉素片(剂量为0.5 bid)和阿莫西林胶囊(剂量为1.0 bid)等药物治疗。实验组则在对照组基础之上另以双歧四联活菌(剂量为1.5 tid)药物治疗。对比两组疗效和治疗后不良反应,以及治疗依从性情况。结果:实验组的根除率为86.67%(26/30),显著高于对照组的63.33%(19/30);未根除率为13.33%(4/30),显著低于对照组的36.67%(11/30)。实验组有不良反应者8例,占比26.67%,显著少于对照组的17例,占比56.67%;实验组在治疗后的依从性为好者占比90.00%(27/30),显著高于对照组的66.67%(20/30),依从性为差者占比10.00%(3/30),显著低于对照组的33.33%(10/30),差异均有统计学意义(均P0.05)。结论:双歧四联活菌采用多药联合方式可明显提升对于Hp的根除率,同时减少不良反应,增加病患依从性。效果显著,值得临床推荐。

Clinical Efficacy Observation of Bifidobacterium Tetravaccine Multi-drug Combination for the Patients with Eradication of Helicobacter Pylori

Objective:To study clinical efficacy observation of Bifidobacterium tetravaccine multi-drug combination for the patients with eradication of ( Helicobacter pylori).Methods:Between March 2012 and March 2013, a total of 60 cases of patients with abdominal discomfort got treatment. Number randomly divided them into the experimental group and the control group. The control group was treated with esomeprazole magnesium enteric-coated tablets (dose of 20mg bid) and colloidal bismuth sodium tartrate (dose of 165mg qid) and clarithromycin tablets (dose of 0.5 bids) and amoxicillin (dose of 1.0 bid) and other drugs. On the basis of the control group, the experimental group was added with Bifidobacterium tetravaccine (dose of 1.5 tid) drug for treatment. Compare the treatment efficacy and adverse reactions, and treatment compliance situation between the two groups.Results:The eradication rate of the experimental group was 86.67%( 26 /30 ), which was significantly higher than the control group of 63.33%( 19/30 ). The not-eradicated rate of experimental group was 13.33% ( 4/30 ), which was significantly lower than the control group of 36.67% ( 11 /30 ). The experimental group''s adverse reactions was 8 cases, accounting for 26.67%, while in control group 17 cases had adverse reactions, accounting for 56.67%; 90.00% of patients ( 27 /30 ) in the experimental group had good compliance after treatment, which was significantly higher than the control group of 66.67% ( 20/30 ). Only 10.00% of patients ( 3 /30 )in experimental group showed poor compliance which was significantly lower than the control group of 33.33%( 10/ 30 ). The differences were statistically significant ( both P <0.05).Conclusion:Bifidobacteriumtetravaccine multi -drug combination can significantly improve Hp eradication rate reduce adverse reactions, and increase patients'' compliance. Its effect is significant and it is worthy of recommendation.